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Abstract
Background & Aims: Patients with decompensated cirrhosis are susceptible to infection. Innate immune dysfunction and
development of organ failure are considered to underlie this. A rodent model of liver disease sharing these phenotypic fea-
tures would assist in vivo study of underlying mechanisms and testing of therapeutics. We evaluated three models to identify
which demonstrated the greatest clinical and immunological phenotypic similarity to patients with acutely decompensated
(AD) cirrhosis. Methods: We selected Bile Duct Ligation (BDL) rats at 4 weeks, BDL mice at 14 days and Carbon tetrachlo-
ride (CCl4) mice at 10 weeks (with studies performed 7 days after final CCl4 infection). We examined organ dysfunction,
inflammatory response to carrageenan-in-paw, plasma eicosanoid concentrations, macrophage cytokine production and
responses to peritoneal infection. Results: Bile duct ligation caused sarcopenia, liver, cardiovascular and renal dysfunction
whereas CCl4 mice demonstrated no clinical abnormalities. BDL rodents exhibited depressed response to carrageenan-in-
paw unlike CCl4 mice. BDL rats have slightly elevated plasma eicosanoid levels and plasma showed partial PGE2-mediated
immune suppression whereas CCl4 mice did not. Plasma NOx was elevated in patients with acute or chronic liver failure
(AoCLF) compared to healthy volunteers and BDL rodents but not CCl4 mice. Elevated nitric oxide (NO) via inducible nitric
oxide synthase (iNOS) mediates defective leucocyte trafficking in BDL rodent models. Conclusions: We conclude that BDL
mice and rats are not simply models of cholestatic liver injury but may be used to study mechanisms underlying poor out-
come from infection in AD and have identified elevated NO as a potential mediator of depressed leucocyte trafficking.
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Background and aims
Around 0.1% of the European population are estimated
to have cirrhosis (1) with an estimated 170 000 deaths
per year (2). Irrespective of the underlying cause,
decompensation of cirrhosis represents the end stage of
the disease process and carries a substantial burden of
morbidity and mortality (3). These patients require fre-
quent hospital admission for bacterial infections, which
represent a major cause of decompensation and death.
Abbreviations
BDL, bile duct ligation; CCl4, carbon tetrachloride; NO, nitric oxide; PG, prostaglandin.
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These patients are highly susceptible (4) to infection
with innate immune dysfunction long considered to
represent a major underlying cause of this increased risk
(4–6). In addition, outcome following infection is more
severe compared to patients with other chronic condi-
tions (7, 8) and has been shown to be directly related to
the development of organ dysfunction (9).
We have recently identified the up regulation of cir-
culating prostaglandin (PG) E2 as a potential key media-
tor underlying immunosuppression in patients with
acute decompensation of cirrhosis (10). Previous studies
have identified other important factors underlying the
poor outcome of infection in these patients. These
include reduced leucocyte trafficking to the site of
infection, bacterial translocation leading to endotoxin
tolerance, elevated circulating nitric oxide (NO) (11),
adaptive immune dysfunction, complement activation,
malnutrition, propensity to renal failure and cardiovas-
cular collapse (12). A rodent model of liver disease that
shared these phenotypic features would greatly assist
in vivo study of the mechanisms underlying this poor
outcome and for testing of potential therapeutics. How-
ever, rodent models are unpopular as they poorly reflect
the liver disease process in humans which characteristi-
cally takes place over 10–30 years (13). Nevertheless, we
found previously that both the bile duct ligated (BDL)
at 14 days and the carbon tetrachloride (CCl4; sampling
within 24 h of final injection) mice models both
demonstrated an up regulation of circulating PGE2 and
leucocyte dysfunction similar to that seen in acute
decompensation patients. Bile duct-ligated rats have
also been used to study infection and cirrhosis (14).
Our aim was to select a model that was likely to reflect
a patient with well-compensated cirrhosis in which
immune function is considered to be broadly intact (15)
and use this as our control and reasoned that cirrhotic
CCl4 mice that had been given 1 week to recover from
their last injection might be representative. We had
already studied the BDL mouse model at 2 weeks which
had shown immune suppression secondary to an up reg-
ulation of PGE2(10) and therefore this model was
selected to interrogate other potentially important fac-
tors in the response to infection in liver disease. As a
comparator, we selected the Rat BDL model at 4 weeks
as this leads to cirrhosis rather than just mild fibrosis as
seen in mice and has been used previously as a model of
AoCLF (14). We therefore hypothesized that this would
be a more clinically relevant model with the added
advantage that, as a larger rodent, it would be able to
tolerate sequential plasma sampling pre- and post-infec-
tious/inflammatory insult or therapeutic intervention
which is not possible with mice.
We aimed therefore to evaluate three models of rodent
liver injury to identify which demonstrated the greatest
clinical and immunological phenotypic similar to
patients with acutely decompensated cirrhosis. We
selected BDL rats at 4 weeks, BDL mice at 14 days and
CCl4 mice at 10 weeks Our studies previously had used a
CCl4 model with studies performed the same day as the
final CCl4 infection to simulate the clinical scenario of
acute decompensation of cirrhosis. However, in these
studies, we elected to use a model with studies performed
7 days after the final CCl4 injection to study a model
that we felt was more likely to replicate an outpatient
with stable liver disease, referred to as chronic CCl4 mice.
Materials and methods
Animal maintenance
Rodents were maintained in a 12/12 h light/dark cycle
at 22  1°C and given food and tap water ad libitum in
accordance. Experiments were performed under UK
Home Office approval according to the Animals (Scien-
tific Procedures) Act 1986. Furthermore, all animals
received human care and that our study protocols
complied with University College London’s guidelines.
Studies were performed in male Sprague–Dawley rats
(220–250 g) and C57Bl6/J mice (20–25 g), both from
Charles River UK, Margate, UK. Approximately, 135
animals were used in total for these experiments.
Liver injury
Bile duct ligation/sham procedures were carried out under
anaesthesia (isoflurane 1.5%) as described previously.
Carbon tetrachloride (CCl4; Merck, Darmstadt, Germany)
was given subcutaneously (s.c., 1:1 dissolved in olive oil;
1 ml/kg) twice weekly and 300 mg/L phenobarbital added
to drinking water. Sham mice received s.c. injections of
Key points
• BDL mouse (2 weeks) and rat (4 weeks) models
both exhibit clinical and biochemical features that
occur in patients with acutely decompensated (AD)
cirrhosis whereas the CCl4 mouse (10 weeks) model
has no phenotypic changes and only an elevated AST
on blood testing similar to patients with stable cirrhosis.
• AD patients characteristically demonstrate both sig-
nificant inflammation and cirrhosis on liver biopsy.
CCl4 mice and BDL rats are cirrhotic but have no/few
inflammatory cells present whereas BDL mice livers
have significant inflammation but only mild fibrosis.
• BDL mice and rats share several innate immune
defects and clinical characteristics with acutely de-
compensated cirrhosis patients whereas the chronic
CCl4 mouse model displayed no clinical or immuno-
logical abnormalities.
• We recommend that the combination of clinical,
biochemical and immune features observed in BDL
rodents make these appropriate models for the study
of infection in advanced liver disease. However, only
the mice have significantly elevated plasma levels of
PGE2 as seen in humans.
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olive oil. After 14 days for BDL mice, 28 days for BDL
rats or 10 weeks for CCl4 mice, either peritonitis or paw
swelling models were carried out or blood/liver/paws were
taken, decalcified (paws only) and prepared for histology
or further experimental use. Unlike our previous study,
CCl4 mice were left for 1 week after the final injection of
CCl4 prior to experimental study. Antibiotics were not
administered to the rodents at any stage.
Peritonitis and paw swelling models
About 0.1 mg Zymosan A (Sigma-Aldrich, Homefield
Road, Haverhill , Suffolk) in 500 ll was injected i.p. to
mice. Peritoneal cavities were washed out 4 h later with
leucocytes prepared for flow cytometry and cell-free
inflammatory exudates stored for further analysis. 1%
carrageenan was injected intraplantar to rodents (100 ll
for rats; 50 ll mice) with equivalent volume saline
injected into the contralateral paw. Inflammation was
presented as difference in paw thickness over time using
gauge (POCO 2T; Kroeplin, GmbH, Surrey, UK) .
Flow cytometry, cytokines and NO
Flow cytometry analysis was performed using FLOWJO
(Tree Star Inc, Ashland, OR, USA). All samples were
analysed on a FACS-LSRII or Fortessa (both BD Bio-
sciences, Oxford, UK). Leucocytes were incubated with
antibodies to F4/80 (clone BM8; eBioscience), murine
CD3 (clone KT3; Serotec, Kidlington, UK), CD19 (clone
6C5; Serotec), GR1 (clone RB6-8C5; BD Pharmingen,
San Diego, CA, USA) using respective isotype antibodies
and FMOs as controls and compensated for dual label-
ling. Cytokine expression profiles were measured by ded-
icated ELISA (TNFa, IL6 and IL10 – mouse eBioscience,
San Diego, CA, USA, R&D systems, Abingdon, UK).
Samples were run in duplicate. NOx was measured as
total nitrite and nitrate in samples deproteinated by
ultra-centrifugation followed by nitrate reductase assay
and Griess Reaction and confirmed using chemilumines-
cence.
Mouse blood analysis and macrophage isolation/culture
Peritoneal macrophages from healthy animals were
isolated as described previously and incubated with/
without LPS (Salmonella Typhosa, 0.1 lg/ml for 24 h;
Sigma-Aldrich) in the presence of plasma from na€ıve,
sham, CCL4 or BDL rodents in cell culture media
(complete DMEM; Life TechnologiesTM, Paisley, UK)
(eBioscience). Samples were run in duplicate.
Human blood analysis and macrophage isolation/culture
Patient’s samples were provided from DASIMAR
UKCRN [University College Hospital London Hospitals’
(UCLH) research ethics committee number:08/H0714/8],
while healthy volunteers were used as controls. Peripheral
venous blood was collected into 5 IU/ml heparin. Plasma
was assayed for NOx as described above for mice.
Extraction and analysis of lipid mediators
Lipid mediators in mice plasma were analysed by liquid
chromatography coupled to electrospray ionization tan-
dem mass spectrometry (LC/ESI-MS/MS) based on pro-
tocols published previously (16, 17). Briefly, samples
were collected and stored immediately at 80°C. Plasma
Samples (250–500 ll) were defrosted on ice and
adjusted to 15% (v/v) methanol: water (final volume
4 ml). Internal standards, PGB2-d4 (40 ng) and 12-
HETE-d8 (40 ng) (Cayman Chemical Company, Ann
Arbor, MI, USA) were added and the pH of resulting
solutions adjusted to 3.0 (1M HCL). Acidified samples
were immediately applied to preconditioned solid-phase
cartridges (C18-E; Phenomenex, Macclesfield, UK) and
lipid mediators eluted with methyl formate. LC/ESI-MS/
MS analysis was performed on a HPLC pump (Waters
Alliance 2695, Hertfordshire, UK) coupled to an electro-
spray ionization triple quadruple mass spectrometer
(Quattro Ultima, Waters, UK). Chromatographic sepa-
ration was performed on a C18 Luna column (5 lm,
150 9 2.0 mm; Phenomenex) for eicosanoids and a C18
Kinetex column (2.6 lm, 100 9 2.1 mm; Phenomenex)
for hydroxy- fatty acids. Quantitative analysis was based
on multiple reaction monitoring-based assays as
reported (15,16) with the following additions: 15-hy-
droxyeicosatrienoic acid (HETrE) m/z 321 > 221, 10-
hydroxydocosahexaenoic acid (HDHA) m/z 343 > 153,
14-HDHA m/z 343 > 161, 13-HDHA m/z 343 > 193
and 17-HDHA m/z 343 > 201. Calibration lines were
constructed using commercially available standards
(Cayman).
Interventional models: peritonitis and intra-venous
bacterial inoculation
Group B Streptococcus (GBS) (NCTC10/84, serotype
V) was grown in Todd Hewitt broth without agitation
at 37°C to an OD600 of 0.4, equivalent to 108 colony
forming units (CFU)/ml, centrifuged/washed with ster-
ile PBS and injected intraperitoneally (i.p.) at 30 9 106
colony forming units (CFUs) in 300 ll sterile PBS for
bacterial killing assays. The nitric oxide synthase (NOS)
inhibitors 1400W or L-NAME (10 mg/kg s.c. or
50 mg/kg po and s.c.; Sigma-Aldrich) were adminis-
tered to mice 1 h prior to zymosan or bacterial
challenge. Following bacterial challenge, mice were sac-
rificed at 3 h after GBS injection, heparinized blood
taken, centrifuged (10 000g, 4°C, 10 min), plated on
agar overnight and CFUs counted the following day.
Data from sham and streptococcus was obtained at
the same time as experiments previously published (10)
as intervention with L-NAME was performed at the
same time to enable us to be adherent to the 3Rs princi-
ple of animal research.
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Evaluation of Organ dysfunction
Liver/Renal
Blood was collected by intracardiac puncture into heparin
and centrifuged (10 000g, 4°C, 10 min). Plasma was anal-
ysed for liver and renal function tests using the COBAS
INTEGRA 400 plus multianalyser with appropriate diag-
nostic kits (Roche – Diagnostics, Burgess Hill, UK) or
stored at80°C.
Echocardiography
Two-dimensional images were recorded using echocar-
diograph (VIVID 7 dimension; GE Vingmed, West
Sussex, UK) with epicardial probe (model i13L; GE
Vingmed). For mean arterial blood pressure, arterial
catheters were inserted under isoflurane (1.5%) and
pressure recorded onto a precalibrated PowerLab system
(ADInstruments, Oxford, UK) (18).
Statistical analysis
For calculation of group sizes, from experiments with
murine peritonitis, cellular profiles, inflammatory pro-
tein expression and lipid mediator production is extre-
mely reproducible. We consider an effect size of ~40% of
parameter mean biologically relevant. To enable statisti-
cal determination at a P < 0.05 in a primary ANOVA screen
followed by post-hoc Bonferroni corrected T-test at 90%
power, a group size of six animals is necessary with a
maximum of five groups per experiment. Applying this
approach to humans using human cirrhotic plasma
nitrite levels a minimum of n = 10/group was required.
Statistical analysis was performed using GraphPad Prism
4 (GraphPad Software). For comparisons between multi-
ple groups, one-way ANOVA with repeated measures
was performed followed by Bonferroni post-test. Com-
parisons between two groups were made by 2-tailed (un)
paired t test. No data were excluded from analysis.
Results
Evaluation of organ dysfunction assessment
Bile Duct Ligation causes organ dysfunction as opposed to
CCl4 model of liver injury
BDL mice demonstrated significant weight loss of 20%
and mice were hypothermic. Detailed cardiac assess-
ment revealed that peak velocity, stroke volume and
heart rate all fell significantly in BDL mice by day 14
(n = 12, P < 0.001, Table 1). To exclude hypothermia
as a cause of cardiovascular dysfunction, we heated
BDLs to the same core temperature as shams. This had
no effect on peak velocity or stroke volume but raised
heart rate from 431 (15) to 494 (10) (P < 0.01) com-
pared to shams rate of 547 (16). Sham operated cardiac
values were identical to naive mice (Table 1). Our previ-
ous study demonstrated that BDL mice had grossly ele-
vated serum bilirubin values, significant rises in
transaminases, reduced serum albumin and creatinine
was elevated (listed in Table 1 for comparison). CCl4
mice displayed no cardiovascular changes or weight loss
and an elevation in AST was the only blood test abnor-
mality. BDL rats showed marked changes in liver blood
tests and significant weight loss but remained
normothermic.
Liver histology
We have previously demonstrated that histological
analysis of mouse BDL liver revealed a chronic inflam-
matory infiltrate of lymphocytes, eosinophils and plasma
Table 1. Clinical and biochemical data for rodents  liver injury (n = 5–10 animals per group)
Sham rat BDL rat Na€ıve mouse Sham mouse BDL mouse CCl4 mouse
Albumin (g/L) 39 (1.6) 30 (1) ** 29 (3) 29 (1) 24 (2) ** 30 (1.5)
ALT (IU/L) 60 (13) 91 (11) 20 (9) 26 (2.4) 340 (33) *** 42 (4)
AST (IU/L) 87 (23) 443 (60) ** 68 (11) 94 (18) 496 (55) 127 (23)*
Total Protein (g/L) 46 (11) 58 (1.3) 41 (3) 43 (2) 32 (2.7) ** 42 (6.6)
Glucose (mmol/L) 12 (1) 7.5 (0.3) 15 (0.2) 12 (1) 6 (1) 10 (1.6)
Bilirubin (umol/L) 2 (0.2) 192 (15) *** 12 (4) 17 (2.9) 380 (35) *** 3 (1)
Creatinine (umol/L) 27 (3) 26 (1.5) 9 (0.7) 11 (0.3) 27 (2.6) ** 10 (1)
Urea (mmol/L) 6 (1) 8 (0.6) 9 (0.7) 8 (0.4) 9 (0.9) 8 (1)
Cardiac assessment
Peak Velocity (m/s) 0.96 (0.04) 0.67 (0.04) *** 1 (0.06)
Stroke volume (ll) 49 (2.4) 37 (1.9) *** 50 (3.3)
Heart rate (BPM) 547 (16) 431 (15) *** 591 (12)
Temperature (°C) 35 (0.8) 36.4 (0.2) 37.8 (0.2) 37.6 (0.1) 35.1 (0.2) ** 37.8 (0.1)
Age at surgery – – 11 weeks 11 weeks 11 weeks 11 weeks
Weight at experiment (g) 455 (6) 375 (10) 27.8 (0.6) 27 (0.4) 19.4 (0.3) *** 31 (0.4)
Plasma Nitrite (lM) 9.2 (1) 51 (16) 50.5 (9.6) 91 (12) ** 22 (4)
*P < 0.05; **P < 0.01; ***P < 0.001, t-test for BDL or CCl4 vs na€ıve or sham mice.
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cells but no fibrosis (10). Heamatoxylin and eosin (H&E)
(Fig. 1a-i) and elastic van gieson (EVG) (Fig. 1a-iii)
staining of BDL rat livers demonstrated cirrhosis, marked
ductular reaction but little inflammation was observed
whilst cirrhotic nodules but no without inflammation
were seen in CCL4 mouse livers (Fig. 1b-i).
(i) (ii) (iii)
(a)
(i)
(b)
(ii)
(i)
(d)
(ii)
(c)
(i) (ii) (iii)
Fig. 1. (a i) Haematoxylin and Eosin (HE)-stained histological sections of the portal tract of liver from bile duct ligated (BDL) rats showing
ductular reaction and scant inflammation. (a ii) HE-stained histological sections from Sham rats (28 days post procedure). (a iii) Elastica Van
Gieson (EVG) staining of BDL rat liver demonstrating bridging fibrosis. (b i) HE-stained histological sections of the portal tract of liver from
CCl4 mice (at 10 weeks, samples taken one week after final CCl4 injection) showing nodular parenchyma with no inflammation and (b ii)
sham mice. (c) Effect of carrageenan-induced paw oedema (1%, 50 ll intra plantar injection in mice, 100 ll in rats) in (i) BDL mice (14 days
post procedure, n = 9), (ii) CCl4 mice (n = 6) and (iii) BDL in rats (n = 6). Graphs show difference in paw size between carrageenan-injected
and saline-injected paw. (d) Representative sections through rat paw 4 h following carrageenan from (i) sham and (ii) BDL animals. All histol-
ogy slides at magnification 920. For carrageenan experiments 3–6 animals per group were used. Data are represented as mean  SEM.
** < 0.01 ***P < 0.001, ANOVA.
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Evaluation of inflammatory response
Both BDL mice and rats exhibit depressed acute inflamma-
tory response to carrageenan-in-paw swelling
Both BDL rodent models demonstrated a significantly
reduced acute inflammatory response to carrageenan paw
swelling (especially BDL mice) whereas CCl4 mice
responded similar to shams (Fig. 1c i–iii). Histological sec-
tion of the paws confirmed a marked reduction in inflam-
matory cell infiltrate in the BDL rodents (Fig. 1d i and ii).
BDL rats but not Chronic CCl4 mice have elevated plasma
eicosanoid levels
Lipidomic analysis of plasma from BDL rats revealed a
modest non-significant elevation in PGD2 and 15-HETE
and significant rises in 13-HODE, 15R-HETE 14-HDHA
and 17-HDHDA. However, there were no differences in
plasma eicosanoid levels between sham and chronic
CCl4 mice (Table 2). Although we screened for 47
metabolites products of COX and LOX mediated
pathways, only 17 mediators were detected as shown in
Table 2.
Plasma from BDL rats exhibits a partial PGE2-mediated
immune suppressive effect on macrophage function whereas
plasma from chronic CCl4 mice has no immune suppressive
effect
Lipidomic analysis revealed that PGE2 and D2 was
minimally elevated in BDL rats compared to shams
(Table 2 & Fig. 2- a i and ii). In addition, their
serum albumin concentration, which we have demon-
strated modulates the immunosuppressive effects of
PGE2(10), was substantially reduced [from 39 (1.6) to
30 (1) g/L, mean (SEM) see Table 1]. When plasma
from BDL rats was added to mouse peritoneal mac-
rophages we observed a partial reduction in LPS-
induced TNFa production compared to plasma from
shams. This partial effect was attenuated when the
EP1-3/DP selective inhibitor AH6809 was added in vi-
tro or if plasma from BDL rats treated with the non-
selective cyclo-oxygenase inhibitor indomethacin was
added (Fig. 2b-i). There was no effect of BDL rat
plasma on macrophage IL10 production (Fig. 2b-ii).
Chronic CCl4 mice also exhibited a modest but not
significant rise in PGE2 but not D2 (Table 2, Fig. 2c-i
and ii) and the serum albumin was unchanged
compared to shams (Table 1). Plasma from these
animals had no anti-inflammatory effect on mice
peritoneal macrophages (Fig. 2d-i and ii).
We have previously shown that the BDL mouse
model demonstrated PGE2 mediated immune
suppression (10). In view of our overall work, we
decided to use the mouse BDL model as our model of
acute decompensation of liver disease and use the
chronic CCl4 mice as a model of stable cirrhosis.
Comparison of response to peritonitis in experimental
models of acute decompensation and stable cirrhosis
Elevated nitric oxide (NO) via inducible nitric oxide synthase
(iNOS) mediates defective leucocyte trafficking and function
in bile duct-ligated rodent models of Liver injury
Plasma NOx was elevated in patients admitted with
acute or chronic liver failure (AoCLF) compared to
healthy volunteers and in bile duct-ligated rodents but
not in CCl4 mice compared with sham animals
(Table 1, Fig. 3a-i & ii).
Measured
metabolite Sham mice CCL4 mice Sham rat BDL rat
PGE2 0.73 (0.09) 0.9 (0.24) 0.34 (0.04) 0.52 (0.15)
PGD2 0.31 (0.14) 0.18 (0.1) 0.06 (0.01) 0.12 (0.04)
PGF2a 0.88 (0.39) 0.67 (0.39) 0.34 (0.15) 0.44 (0.2)
TXB2 2.24 (1.12) 1.67 (0.96) 0.91 (0.41) 0.83 (0.42)
9-HODE 9.2 (5.3) 11 (4.9) 3.8 (1.7) 5.5 (2.5)
13-HODE 29.3 (17) 34.8 (16) 10.6 (4.7) 66.1 (30)
12-HEPE 20.5 (12) 14.1 (6.3) 0.9 (0.4) 0.7 (0.3)
5-HETE 2.8 (1.6) 4.2 (1.9) 1.1 (0.5) 0.9 (0.4)
8-HETE 2.9 (1.7) 4.6 (2.1) 1 (0.4) 0.7 (0.3)
11-HETE 2.5 (1.4) 3 (1.4) 1.5 (0.6) 0.6 (0.3)
15-HETE 4.2 (2.4) 3 (1.7) 1.9 (0.8) 3.5 (1.6)
12-HETE 276 (159) 378 (170) 37.3 (17) 25.2 (11)
15-HETrE 0.5 (0.3) 0.8 (0.4) 0.2 (0.1) 1.3 (0.6)
10-HDHA 1.2 (0.7) 1.3 (0.6) 0.04 (0.0) 0.3 (0.2)
14-HDHA 12 (7) 12.4 (5.5) 0.5 (0.2) 3 (1.3)
13-HDHA 0.5 (0.3) 0.8 (0.4) 0.2 (0.1) 0.6 (0.3)
17-HDHA 2.8 (1.6) 4.5 (2) 14 (6.3)
PG, Prostaglandin; TX, Thromboxane; HODE, Hydroxyoctadecaenoic acid; HETE, Hydroxye-
icosaenoic acid; HETEr, hydroxyeicosatrienoic acid; HDHA, Hydroxydocosahexaenoic acid; HEPE,
hydroxy eicosapentaenoic acid.
Table 2. LC/ESI-MS/MS analysis of plasma
from sham & CCL4 mice and sham and BDL
rats for the 47 known metabolites of COX
and LOX enzymes (ng/ml). (n = 5–6 mice
per group)
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We found that following intraperitoneal zymosan
BDL mice demonstrated reduced cell trafficking com-
pared to shams (P < 0.01) (Fig. 3b-i). As BDL mice
were hypothermic, we warmed them to 37.5°C prior to
zymosan but this had no significant effect on leucocyte
trafficking (Fig. 3b-i). Conversely, cell trafficking fol-
lowing zymosan was similar between CCl4 mice and
their respective shams (Fig. 3-ii). Flow cytometric
analysis confirmed that GR1 cell numbers were princi-
pally affected in the BDL mice (Fig. 3c). This reduced
leucocyte trafficking was completely reversed following
NO synthase (NOS) inhibition by both the non-selective
inhibitor NOS inhibitor L-NAME and the highly selec-
tive iNOS inhibitor (1400W) (Fig. 3d-i and ii).
Finally BDL mice were injected with live Group B
streptococcus (GBS, NCTC10/84, serotype V). L-NAME
partially restored bacterial killing towards sham levels
(Fig 3d-iii).
Discussion
Infection is one of the major causes of decompensa-
tion and death in advanced liver disease and therefore
the development of more effective treatments against
this represents a major challenge for hepatologists
(12). Several defects in the innate immune response
have been demonstrated in these patients including
our recent identification of PGE2 mediated leucocyte
dysfunction (3). In vivo testing of novel treatments is
extremely difficult in patients with advanced liver dis-
ease and therefore development of representative
rodent models of the associated innate immune dys-
function is extremely important. As well as immune
dysfunction, extra hepatic organ dysfunction has
emerged as a key indicator of poor prognosis follow-
ing infection (9) and therefore an ideal model would
exhibit both of these features. In this study, we have
shown that BDL mice and rats share several innate
immune defects and clinical characteristics with
acutely decompensated cirrhosis patients whereas the
chronic CCl4 mouse model displayed no clinical or
immunological abnormalities (see Table S1). Although
BDL mice have little histological similarity to acutely
decompensated cirrhosis unlike the rats which demon-
strate cirrhosis, they do have significantly elevated
plasma levels of PGE2 as seen in humans.
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Fig. 2. (a) Lipidomic analysis demonstrated that (i) PGE2 and (ii) D2 were minimally elevated in BDL rats compared to shams. (b) Plasma from
BDL rats induced a partial reduction in (i) LPS-induced TNFa production from na€ıve mice peritoneal macrophages compared to plasma from
shams which was attenuated when the EP1–3/DP selective inhibitor AH6809 was added in vitro or if plasma from BDL rats treated with indo-
methacin (Indo) was added. (b) Plasma from BDL rats had no effect on (ii) IL10 secretion from na€ıve mice peritoneal macrophages. (c) (i)
PGE2 and (ii) iD2 levels were minimally elevated in plasma from Chronic CCl4 mice but (d) this plasma had no effect on peritoneal macro-
phage LPS-induced (i) TNFa or (ii) IL10 production function compared to sham plasma.
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The BDL mice have severe liver dysfunction, renal
impairment and low blood glucose levels. They demon-
strate sarcopenia and cardiovascular dysfunction. These
are characteristic clinical features of acutely decompen-
sated cirrhosis. It should be noted that, in keeping with
previously published data (19), cardiac output is actu-
ally reduced whereas most commonly a high cardiac
output (20) is observed in acute decompensation
patients. Although increasingly a low output state has
been recognized and correlates with a poor prognosis.
Bile duct ligation in rats induced cirrhosis and
severely deranged liver enzymes, NO levels were signifi-
cantly elevated and carrageenan-in-paw responses were
significantly dampened. However, PGE2 levels were only
minimally elevated and we observed that plasma from
BDL rats could only induce a small reduction in macro-
phage function. We attribute this to the slight increase
in plasma PGE2 combined with the reduction in albu-
min which modulates the effects of PGE2 as albumin is
known to both bind and catalyse E-series prostaglandins
(21). Other groups have successfully used endotoxin
treated BDL rats as model of acute or chronic liver fail-
ure. Although PGE2 is highly likely to be elevated under
such circumstances these models are short term (3 h)
(14) which would not allow time for detailed immune
assessment.
Chronic CCl4 mice had slightly elevated PGE2, nor-
mal plasma NO and albumin concentration and normal
cardiac and renal function, similar to stable cirrhosis
patients (Child Pugh A or low MELD score). Therefore,
whilst appropriate for studying mechanisms that under-
lie fibrosis this is not a relevant model for the study of
immune dysfunction. It is possible that we may have
observed a different result had we used BALB/c mice
which develop fibrosis secondary to CCl4 more readily
than C57BL/6 inbred mice (22). However, for our origi-
nal BDL model studies we had used C57BL/6 mice and
therefore we continued with this breed. This is in
marked contrast to our previous study in which PGE2
levels were elevated acutely following CCl4 injection
(10). This subtle difference in methodology should be
considered when using this model. If the model is
extended to up to 15 weeks decompensation with asci-
tes occurs and immune responses are highly likely to be
altered but again we felt that the associated high mortal-
ity (70%) with this model was unacceptable (23).
We demonstrate that elevated nitric oxide (NO)
impaired cell trafficking in BDL mice but that inhibition
only partially reversed the impaired bacterial killing
observed in these mice compared to shams. Therefore, it is
not clear whether this improvement in trafficking confers
any functional benefit. NO has been shown to be elevated
in patients with advanced cirrhosis and this correlated
with disease severity (24). In vivo neutrophil migration
was decreased in cirrhotic patients with previous episodes
of bacterial infection compared with non-infected patients
using a skin window technique suggesting that deficient
neutrophil recruitment to the infection site may contrib-
ute to increased bacterial infections in cirrhotic patients
with advanced liver disease (25). Further investigation is
required to establish whether NO mediates this process in
acute decompensation patients and furthermore whether
inhibition has a demonstrable effect on the impaired
response to infection in these patients.
The two major criticisms of the 2 week BDL mice
model are the absence of significant liver fibrosis and
that it is a defined surgical procedure rather than the
chronic or repetitive inflammatory insults that occur in
alcohol, viral hepatitis and Non-Alcoholic Steatohepati-
tis (NASH), which account for approximately 90% of
liver disease within the UK (26). Mouse models of
NASH (27) and alcohol (13) induced liver damage do
not reliably cause cirrhosis or advanced liver dysfunc-
tion and were therefore not tested during this study. We
have shown that the chronic inflammatory injury com-
bined with the liver dysfunction observed in this model
create a similar immune suppressive phenotype to that
observed in acute decompensation patients. It would
therefore appear that liver dysfunction rather than fibro-
sis per se is necessary for development of this phenotype.
It has been shown that BDL mice at 6 weeks develop
cirrhosis (28) but we found that these mice lost signifi-
cant amounts of weight leading to an unacceptable mor-
tality. Equally we have focused on only two mediators of
immune dysfunction and there are clearly others;
further work is required to determine whether BDL
mice can be used to study other putative mediators or
mechanisms, although rapid onset of intestinal bacterial
overgrowth (within 1 day) has been demonstrated in
these mice (29) as opposed to 10 weeks for CCl4 mice.
We conclude that BDL mice and rats are not simply
models of cholestatic liver injury but may be used to
Fig. 3. (a i) Plasma nitrite levels in patients admitted to hospital with complications of cirrhosis (CP) compared to healthy volunteers (HV). (a
ii) Plasma NOx levels in sham and liver injury rodents (n = 6 for each group). (b) Total leucocyte count following zymosan-induced peritonitis
in na€ıve, sham & BDL mice  zymosan (Z; 0.1 mg at 4 h) and BDL mice warmed (warm) to the same core temperature as shams (b i) as well
as CCl4 mice (b ii); n = 8–10 – data taken from 3 consecutive experiments. (c) Representative flow cytometry traces of GR1 and F4/80
labelled peritoneal macrophages 4 h after zymosan in na€ıve, sham, BDL and BDL + LNAME mice. These cells are gated on CD3 negative
CD19 negative and CD 11B positive to exclude T and B cells. (d i and ii) Zymosan (0.1 mg) was injected, i.p. to na€ıve, sham and BDL mice
with/without NOS inhibition [1400W (iNOS inhibitor), L-NAME], with peritoneal PMNs showing the greatest reduction in cell numbers with
full reversal seen in the presence of NOS inhibition. (d iii) Colony forming units detected in sham or BDL mouse blood at 3 h following i.p.
injection of Group B streptococcus (GBS, 30 million units per mouse). BDL mice were treated with or L-NAME (50 mg/kg) 30 mins before
bacteria injection. Sham and BDL data as previously shown10, reproduced for this figure as experiments performed using L-NAME were per-
formed together to minimize animal usage.*P < 0.05 **P < 0.01 ***P < 0.001, ANOVA or t-test where appropriate.
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study mechanisms underlying poor outcome from
infection in AD although rats demonstrated only mini-
mally elevated plasma PGE2. We have also identified
elevated NO as a potential mediator of depressed leuco-
cyte trafficking in these models although reversal of this
process did not restore impaired bacterial killing in
mice.
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